This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Clinical Pharmacokinetics Study on Pikamilone

This study has been completed.
Information provided by:
Chinese Academy of Sciences Identifier:
First received: July 14, 2009
Last updated: NA
Last verified: July 2009
History: No changes posted
Study on the phamacokinetics of Pikamilone in healthy Chinese subject and provide informations for further phase II study.


Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Clinical Pharmacokinetics Study on Pikamilone

Further study details as provided by Chinese Academy of Sciences:

Biospecimen Retention:   Samples Without DNA

Enrollment: 30
Study Start Date: March 2009
Study Completion Date: April 2009
low dosage group: administrate pikamilone tablet 50 mg; middle dosage group: administrate pikamilone tablet 100 mg; hige dosage group: administrate pikamilone tablet 200 mg.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
15 male subjects and 15 female subjects were enrolled in this study. They were divided into three groups by random and each group contained 5 male and 5 female subjects.

Inclusion Criteria:

  • nonsmokers and in good health
  • weight: BMI: 19-24
  • written informed consent was finished.

Exclusion Criteria:

  • disease
  • taking any drug, alcohol, foods containing caffeine, or grapefruits and juice before study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00940186

China, Liaoning
the second hospital to liaoning university of TCM
Shenyang, Liaoning, China, 110034
Sponsors and Collaborators
Chinese Academy of Sciences
Study Chair: D F Zhong, PH.D Shanghai Institute of Materia Medica, Chinese Academy of Sciences
  More Information

Responsible Party: center for drug metabolism and pharmacokinetics, shanghai institute of materia medica Identifier: NCT00940186     History of Changes
Other Study ID Numbers: SIMM-DMPK-080901
Study First Received: July 14, 2009
Last Updated: July 14, 2009 processed this record on August 17, 2017